These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 15034159

  • 1. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD, Brandenburg VM, Lanzmich R, Floege J.
    Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
    [Abstract] [Full Text] [Related]

  • 2. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
    Marmur JD, Lakhani M, El Rouby S, Cavusoglu E.
    J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
    [Abstract] [Full Text] [Related]

  • 3. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA, Monitz HG, Fernandez JD, Fazlollah TM, Knezevic A, Miller BE.
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [Abstract] [Full Text] [Related]

  • 4. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
    Frank RD, Müller U, Lanzmich R, Groeger C, Floege J.
    Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
    [Abstract] [Full Text] [Related]

  • 5. In vitro anticoagulation monitoring of low-molecular-weight heparin.
    Wang JQ, Shi XB, Yang JG, Hu DY.
    Chin Med J (Engl); 2009 May 20; 122(10):1199-202. PubMed ID: 19493471
    [Abstract] [Full Text] [Related]

  • 6. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J, Johnston N, Siegbahn A.
    Am Heart J; 2008 Mar 20; 155(3):493.e1-8. PubMed ID: 18294482
    [Abstract] [Full Text] [Related]

  • 7. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E, Lakhani M, Marmur JD.
    J Invasive Cardiol; 2005 Aug 20; 17(8):416-21. PubMed ID: 16079447
    [Abstract] [Full Text] [Related]

  • 8. Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: initial experience.
    Schinzel H, Berghoff K, Beuermann I, Sauer O, von Mach MA, Weilemann LS.
    Transfusion; 2006 Apr 20; 46(4):624-9. PubMed ID: 16584439
    [Abstract] [Full Text] [Related]

  • 9. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J, Haaf B, Dempfle CE, Stehle G, Heene DL.
    Nephrol Dial Transplant; 1995 Apr 20; 10(2):217-22. PubMed ID: 7753456
    [Abstract] [Full Text] [Related]

  • 10. Dalteparin dose-dependently increases ROTEM(®) thrombelastography parameters only at supratherapeutic anti-factor Xa levels: an in vitro study.
    Feuring M, Wehling M, Schultz A.
    Clin Exp Pharmacol Physiol; 2011 Nov 20; 38(11):783-6. PubMed ID: 21883380
    [Abstract] [Full Text] [Related]

  • 11. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD, Oliveira C, Bruges M, Gusmão L, Santana A, Ponce P, Simões J, Freire I, Crespo F, da Silva AN.
    Acta Med Port; 1992 Feb 20; 5(2):65-70. PubMed ID: 1317657
    [Abstract] [Full Text] [Related]

  • 12. Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention.
    Marmur JD, Bullock-Palmer RP, Poludasu S, Cavusoglu E.
    J Invasive Cardiol; 2009 Dec 20; 21(12):653-64. PubMed ID: 19966370
    [Abstract] [Full Text] [Related]

  • 13. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.
    Silvain J, Beygui F, Ankri A, Bellemain-Appaix A, Pena A, Barthelemy O, Cayla G, Gallois V, Galier S, Costagliola D, Collet JP, Montalescot G.
    J Am Coll Cardiol; 2010 Feb 16; 55(7):617-25. PubMed ID: 20170785
    [Abstract] [Full Text] [Related]

  • 14. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S, Wolz M, Nieszpaur-Los M, Schneider B, Lechner K, Eichler HG, Kyrle PA.
    Thromb Haemost; 1994 Dec 16; 72(6):831-5. PubMed ID: 7740450
    [Abstract] [Full Text] [Related]

  • 15. Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis.
    Verhave G, Weijmer MC, van Jaarsveld BC.
    Neth J Med; 2015 Jul 16; 73(6):270-5. PubMed ID: 26228191
    [Abstract] [Full Text] [Related]

  • 16. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT, Monn A, Tavakoli R, Genoni M, Klaghofer R, Furrer L, Honegger H, Hofer CK.
    Eur J Cardiothorac Surg; 2006 Aug 16; 30(2):278-84. PubMed ID: 16828293
    [Abstract] [Full Text] [Related]

  • 17. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Rabbat CG, Cook DJ, Crowther MA, McDonald E, Clarke F, Meade MO, Lee KA, Cook RJ.
    J Crit Care; 2005 Dec 16; 20(4):357-63. PubMed ID: 16310608
    [Abstract] [Full Text] [Related]

  • 18. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets.
    Sagedal S, Hartmann A, Sundstrøm K, Bjørnsen S, Brosstad F.
    Nephrol Dial Transplant; 2001 May 16; 16(5):987-93. PubMed ID: 11328905
    [Abstract] [Full Text] [Related]

  • 19. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS, Murkin JM, Adams SJ.
    Heart Surg Forum; 2004 May 16; 7(6):E599-604. PubMed ID: 15769695
    [Abstract] [Full Text] [Related]

  • 20. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing.
    Näsström B, Stegmayr B, Gupta J, Olivecrona G, Olivecrona T.
    Nephrol Dial Transplant; 2005 Jun 16; 20(6):1172-9. PubMed ID: 15797889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.